Last reviewed · How we verify

NCT05771298

Potassium Titanyl Phosphate Laser Versus Pulsed Dye Laser for Rosacea - a Prospective Study

Status unknown NA Last updated 16 March 2023
What this trial tests

NA trial testing 532nm KTP in Rosacea in 30 participants. Status unknown.

Timeline
1 February 2023
Primary endpoint
1 May 2023
1 June 2023

Quick facts

Lead sponsorUniversitätsklinikum Hamburg-Eppendorf
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment30
Start date1 February 2023
Primary completion1 May 2023
Estimated completion1 June 2023
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Universitätsklinikum Hamburg-Eppendorf — full company profile →

Who can join

18 and older, any sex, with Rosacea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the efficacy and safety of 532 nm KTP and 585 nm PDL for treating rosacea.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. 532-nm potassium titanyl-phosphate laser versus 595-nm pulsed dye laser for port-wine birthmarks: A prospective, randomized, split-side study.
    Nguyen L, Seeber N, Kautz G, Hartjen A, et al · · 2024 · cited 3× · PMID 38794945 · DOI 10.1111/jdv.19750

Verify or expand the search:

Other recruiting trials for Rosacea

Currently open trials in the same condition.

Other Universitätsklinikum Hamburg-Eppendorf trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05771298.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing